Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Baylor Genetics | RCV001332263 | SCV001524521 | pathogenic | Acute intermittent porphyria | 2020-06-03 | criteria provided, single submitter | clinical testing | This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. |
Revvity Omics, |
RCV001332263 | SCV002016602 | likely pathogenic | Acute intermittent porphyria | 2021-02-25 | criteria provided, single submitter | clinical testing | |
Genomic Medicine Center of Excellence, |
RCV001332263 | SCV003924280 | pathogenic | Acute intermittent porphyria | 2023-05-08 | criteria provided, single submitter | research | |
Mayo Clinic Laboratories, |
RCV004793436 | SCV005414023 | pathogenic | not provided | 2024-07-15 | criteria provided, single submitter | clinical testing | PP4, PM2, PVS1 |
Prevention |
RCV003983876 | SCV004800208 | pathogenic | HMBS-related disorder | 2023-10-29 | no assertion criteria provided | clinical testing | The HMBS c.826-2A>T variant is predicted to disrupt the AG splice acceptor site and interfere with normal splicing. This variant has been reported in an individual with acute intermittent porphyria (Table 1, Chen et al. 2019. PubMed ID: 30740734). This variant has not been reported in a large population database (http://gnomad.broadinstitute.org), indicating this variant is rare. Variants that disrupt the consensus splice acceptor site in HMBS are expected to be pathogenic. This variant is interpreted as pathogenic. |